GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » EPS without NRI

Pentixapharm Holding AG (XTER:PTP) EPS without NRI : €-0.30 (TTM As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG EPS without NRI?

Pentixapharm Holding AG's earnings per share without non-recurring items for the six months ended in Jun. 2024 was €-0.09. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Pentixapharm Holding AG's EPS without NRI or its related term are showing as below:

XTER:PTP's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 10.5
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Pentixapharm Holding AG's EPS (Diluted) for the six months ended in Jun. 2024 was €-0.09. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.30.

Pentixapharm Holding AG's EPS (Basic) for the six months ended in Jun. 2024 was €-0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.30.


Pentixapharm Holding AG EPS without NRI Historical Data

The historical data trend for Pentixapharm Holding AG's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG EPS without NRI Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
EPS without NRI
-0.10 -0.08 -0.31

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
EPS without NRI - - -0.10 -0.21 -0.09

Competitive Comparison of Pentixapharm Holding AG's EPS without NRI

For the Biotechnology subindustry, Pentixapharm Holding AG's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pentixapharm Holding AG's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pentixapharm Holding AG's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pentixapharm Holding AG's PE Ratio without NRI falls into.


;
;

Pentixapharm Holding AG EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pentixapharm Holding AG  (XTER:PTP) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pentixapharm Holding AG EPS without NRI Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pentixapharm Holding AG Business Description

Traded in Other Exchanges
Address
Robert-Rossle-Street 10, Berlin, DEU
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines